Episode Details
Back to Episodes
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
Episode 97
Published 4 years, 4 months ago
Description
In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:
- Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
- Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
- Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer
Presenters:
Nicole Concin, MD, PhD
Professor
Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/30PjPnl
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.